Xinli Tai: SAL0150 Receives Clinical Trial Approval Notice

K-LinePoet · 2026-03-23T18:40:49+00:00

Xinli Pharma announced that the company recently received a "Clinical Trial Approval Notice" officially signed and issued by the National Medical Products Administration, which approved the clinical trials for SAL0150 tablets, an innovative drug independently developed by the company, in patients with type 2 diabetes for indications including blood glucose control, obesity or overweight, and type 2 diabetes with peripheral arterial disease accompanied by intermittent claudication.

K-LinePoet

2026-03-23 18:40:49

Xinli Tai announces that recently, the company received the “Clinical Trial Approval Notice” issued by the National Medical Products Administration, approving the company’s self-developed innovative drug SAL0150 tablets to conduct clinical trials for blood sugar control in type 2 diabetes patients, obesity or overweight, and type 2 diabetes combined with peripheral arterial disease with intermittent claudication.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.